HK1212616A1 - 多孔載體顆粒和微粒化藥物的可吸入團聚物 - Google Patents

多孔載體顆粒和微粒化藥物的可吸入團聚物

Info

Publication number: HK1212616A1
Authority: HK; Hong Kong
Prior art keywords: carrier particles; porous carrier; micronized drug; respirable agglomerates; respirable
Prior art date: 2013-03-14

Application number

HK16100598.8A

Other languages

English (en)

Inventor

Michael Hartman

Thomas Tarara

Patrick Teung

Jeffry Weers

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-14

Filing date

2016-01-20

Publication date

2016-06-17

2016-01-20 Application filed by Novartis Ag filed Critical Novartis Ag

2016-06-17 Publication of HK1212616A1 publication Critical patent/HK1212616A1/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Inorganic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HK16100598.8A 2013-03-14 2016-01-20 多孔載體顆粒和微粒化藥物的可吸入團聚物 HK1212616A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361784842P	2013-03-14	2013-03-14
PCT/IB2014/059739 WO2014141135A1 (en)	2013-03-14	2014-03-13	Respirable agglomerates of porous carrier particles and micronized drug

Publications (1)

Publication Number	Publication Date
HK1212616A1 true HK1212616A1 (zh)	2016-06-17

Family

ID=50478894

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK16100598.8A HK1212616A1 (zh)	2013-03-14	2016-01-20	多孔載體顆粒和微粒化藥物的可吸入團聚物

Country Status (22)

Country	Link
US (2)	US9452139B2 (zh)
EP (1)	EP2968570A1 (zh)
JP (1)	JP6374414B2 (zh)
KR (1)	KR20150129716A (zh)
CN (1)	CN105188757B (zh)
AU (2)	AU2014229265A1 (zh)
BR (1)	BR112015021814A2 (zh)
CA (1)	CA2905615A1 (zh)
CL (1)	CL2015002632A1 (zh)
EA (1)	EA201591729A1 (zh)
GT (1)	GT201500295A (zh)
HK (1)	HK1212616A1 (zh)
IL (1)	IL240963A (zh)
MA (1)	MA38397A1 (zh)
MX (1)	MX2015012814A (zh)
PE (1)	PE20151655A1 (zh)
PH (1)	PH12015501882A1 (zh)
SA (1)	SA515361055B1 (zh)
SG (1)	SG11201506397QA (zh)
TN (1)	TN2015000395A1 (zh)
WO (1)	WO2014141135A1 (zh)
ZA (1)	ZA201505768B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3219705T3 (da)	2005-12-28	2020-04-14	Vertex Pharma	Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
TWI433674B (zh)	2006-12-28	2014-04-11	Infinity Discovery Inc	環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP2560954B1 (en)	2010-04-22	2016-10-05	Vertex Pharmaceuticals Incorporated	Process of producing cycloalkylcarboxamido-indole compounds
SG11201505556VA (en) *	2013-01-31	2015-08-28	Prosonix Ltd	Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
US9452139B2 (en) *	2013-03-14	2016-09-27	Novartis Ag	Respirable agglomerates of porous carrier particles and micronized drug
KR20160137543A (ko) *	2014-03-27	2016-11-30	노파르티스 아게	활성 약제 성분의 흡입을 위한 분무-건조되는 수-중-유-중-고체 분산액
SI3925607T1 (sl)	2014-04-15	2023-10-30	Vertex Pharmaceuticals Incorporated	Farmacevtski sestavki za zdravljenje bolezni, ki jih povzroča regulator transmembranske prevodnosti pri cistični fibrozi
WO2016057730A1 (en)	2014-10-07	2016-04-14	Strohmeier Mark	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016142708A2 (en) *	2015-03-10	2016-09-15	Cipla Limited	Pharmaceutical composition
US10423736B2 (en) *	2015-08-28	2019-09-24	University Of British Columbia	Methods and systems for simulating hydrodynamics in gas-solid fluidized beds
EP3335699A1 (en)	2016-12-15	2018-06-20	H e x a l Aktiengesellschaft	Selexipag formulation in liquisolid system
CN106943350A (zh) *	2017-03-14	2017-07-14	上海现代药物制剂工程研究中心有限公司	含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
WO2019060595A1 (en) *	2017-09-20	2019-03-28	Teva Branded Pharmaceutical Products R&D, Inc.	INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US20200324064A1 (en) *	2019-04-10	2020-10-15	Cai Gu Huang	Inhalation Device for Administering Powdered Pharmaceutical Composition
US20200375945A1 (en) *	2019-06-03	2020-12-03	Cai Gu Huang	Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
CN112137957B (zh) *	2019-06-26	2022-07-29	长风药业股份有限公司	一种药用吸入气雾剂及其制备方法
CN114206137A (zh) *	2019-08-15	2022-03-18	雅培制药有限公司	使用微粉化的营养粉末制造方法和粉末组合物
KR20220167315A (ko) *	2020-04-13	2022-12-20	유니버지퇴트슈피탈 바젤	Lsd 용량 확인
CN114344285B (zh) *	2020-10-14	2023-11-14	江苏恒瑞医药股份有限公司	改良的可吸入团聚物
TW202237102A (zh) *	2020-12-11	2022-10-01	大陸商江蘇恒瑞醫藥股份有限公司	用於肺部遞送的藥物組合物
CN113318097A (zh) *	2021-04-29	2021-08-31	珠海瑞思普利医药科技有限公司	一种抗特发性肺纤维化的粉雾剂及制备方法
CN117357485B (zh) *	2023-11-01	2024-09-24	山东京卫制药有限公司	一种改良的可吸入的载体颗粒及应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2956062A (en)	1959-02-26	1960-10-11	Robins Co Inc A H	Esters of amino alcohols
IT1016489B (it)	1974-03-18	1977-05-30	Isf Spa	Inalatore
CY1359A (en)	1981-02-02	1987-08-07	Schering Corp	Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
SE448277B (sv)	1985-04-12	1987-02-09	Draco Ab	Indikeringsanordning vid en doseringsanordning for lekemedel
US6536427B2 (en)	1990-03-02	2003-03-25	Glaxo Group Limited	Inhalation device
ES2086759T3 (es)	1991-06-26	1996-07-01	Schering Corp	Dispositivo de inhalacion para medicamentos en polvo.
AU683036B2 (en)	1992-12-18	1997-10-30	Merck Sharp & Dohme Corp.	Inhaler for powdered medications
US6794357B1 (en) *	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US5837699A (en)	1994-01-27	1998-11-17	Schering Corporation	Use of mometasone furoate for treating upper airway passage diseases
ES2302332T3 (es)	1994-09-21	2008-07-01	Nektar Therapeutics	Aparato y metodos para dispersar medicamentos en polvo seco.
JP2000503565A (ja)	1996-01-03	2000-03-28	グラクソ、グループ、リミテッド	吸入装置
UA49878C2 (uk)	1996-02-21	2002-10-15	Шерінг Корпорейшн	Пристрій для інгаляції порошку (варіанти)
US6613795B2 (en)	1996-11-11	2003-09-02	Christian Noe	Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
PT937041E (pt)	1996-11-11	2003-09-30	Christian R Noe	Utilizacao de um sal farmaceuticamente aceitavel de (3r,2'r)-3-¬(ciclopentil-hidroxifenilacetil)oxi\|-1,1-dimetil-pirrolidinio para a preparacao de um medicamento
US6010935A (en)	1997-08-21	2000-01-04	Micron Technology, Inc.	Self aligned contacts
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
UA73924C2 (en)	1998-10-09	2005-10-17	Nektar Therapeutics	Device for delivering active agent formulation to lungs of human patient
US20070212422A1 (en)	1999-11-10	2007-09-13	Manfred Keller	Dry powder for inhalation
ATE382386T1 (de)	1998-11-13	2008-01-15	Jagotec Ag	Multidosis-trockenpulverinhalator mit pulverreservoir
GB9913083D0 (en)	1999-06-04	1999-08-04	Novartis Ag	Organic compounds
JP4377076B2 (ja)	1999-05-28	2009-12-02	ネクターセラピューティクス	噴霧化された薬物の計量された量を投与する装置と方法
US6679256B2 (en)	1999-12-17	2004-01-20	Nektar Therapeutics	Systems and methods for extracting powders from receptacles
US7069929B2 (en)	2000-02-01	2006-07-04	Quadrant Technologies Limited	Dry powder inhaler
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
MXPA02001323A (es)	2000-05-10	2004-07-16	Alliance Pharma	Microgranulos con base fosfolipida para la liberacion de farmaco.
GB0201677D0 (en)	2002-01-25	2002-03-13	Glaxo Group Ltd	Medicament dispenser
CA2509216A1 (en)	2002-12-13	2004-07-01	Adagit	Pharmaceutical porous particles
KR101066788B1 (ko)	2003-04-09	2011-09-21	노바르티스 아게	공기 입구 차폐 부재를 갖춘 에어로졸화 장치
GB0317374D0 (en)	2003-07-24	2003-08-27	Glaxo Group Ltd	Medicament dispenser
GB2407042B (en)	2003-10-17	2007-10-24	Vectura Ltd	Inhaler
CN100589849C (zh)	2004-02-24	2010-02-17	微计量技术有限公司	基于合成射流的药物输送方法和装置
GB0410712D0 (en)	2004-05-13	2004-06-16	Novartis Ag	Organic compounds
GB0413960D0 (en)	2004-06-22	2004-07-28	Novartis Ag	Organic compounds
ITMI20051999A1 (it)	2005-10-21	2007-04-22	Eratech S R L	Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0613161D0 (en) *	2006-06-30	2006-08-09	Novartis Ag	Organic Compounds
MY150468A (en)	2006-06-30	2014-01-30	Novartis Ag	Quinolinone derivatives and their pharmaceutical compositions
KR101501784B1 (ko)	2006-10-25	2015-03-11	노파르티스 아게	분말 분산 장치, 이 장치를 제작 및 사용하는 방법, 및 장치 및 기타 기기 상에서 사용될 수 있는 구성요소
JP5727927B2 (ja)	2008-05-15	2015-06-03	ノバルティスアーゲー	フルオロキノロンの肺送達
US20120022127A1 (en)	2009-04-09	2012-01-26	Thomas Allmendinger	Process for preparing pyrrolidinium salts
US8815258B2 (en) *	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
RU2585101C2 (ru)	2010-04-01	2016-05-27	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Способ приготовления частиц носителя для сухих порошков для ингаляции
JOP20120023B1 (ar)	2011-02-04	2022-03-14	Novartis Ag	صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) *	2013-03-14	2016-09-27	Novartis Ag	Respirable agglomerates of porous carrier particles and micronized drug

2014
- 2014-03-10 US US14/202,262 patent/US9452139B2/en active Active
- 2014-03-13 EP EP14716933.8A patent/EP2968570A1/en not_active Withdrawn
- 2014-03-13 AU AU2014229265A patent/AU2014229265A1/en not_active Abandoned
- 2014-03-13 BR BR112015021814A patent/BR112015021814A2/pt active Search and Examination
- 2014-03-13 KR KR1020157024586A patent/KR20150129716A/ko not_active Application Discontinuation
- 2014-03-13 CA CA2905615A patent/CA2905615A1/en not_active Abandoned
- 2014-03-13 MX MX2015012814A patent/MX2015012814A/es unknown
- 2014-03-13 EA EA201591729A patent/EA201591729A1/ru unknown
- 2014-03-13 WO PCT/IB2014/059739 patent/WO2014141135A1/en active Application Filing
- 2014-03-13 PE PE2015001910A patent/PE20151655A1/es not_active Application Discontinuation
- 2014-03-13 CN CN201480015125.XA patent/CN105188757B/zh active Active
- 2014-03-13 MA MA38397A patent/MA38397A1/fr unknown
- 2014-03-13 SG SG11201506397QA patent/SG11201506397QA/en unknown
- 2014-03-13 JP JP2015562509A patent/JP6374414B2/ja active Active
2015
- 2015-08-11 ZA ZA2015/05768A patent/ZA201505768B/en unknown
- 2015-08-26 PH PH12015501882A patent/PH12015501882A1/en unknown
- 2015-08-31 IL IL240963A patent/IL240963A/en active IP Right Grant
- 2015-09-04 TN TN2015000395A patent/TN2015000395A1/en unknown
- 2015-09-11 CL CL2015002632A patent/CL2015002632A1/es unknown
- 2015-09-13 SA SA515361055A patent/SA515361055B1/ar unknown
- 2015-09-14 GT GT201500295A patent/GT201500295A/es unknown
2016
- 2016-01-20 HK HK16100598.8A patent/HK1212616A1/zh unknown
- 2016-08-17 US US15/238,842 patent/US9744178B2/en active Active
2017
- 2017-05-16 AU AU2017203258A patent/AU2017203258B2/en active Active

Also Published As

Publication number	Publication date
MX2015012814A (es)	2016-02-03
IL240963A0 (en)	2015-11-30
ZA201505768B (en)	2017-03-29
AU2017203258A1 (en)	2017-06-08
AU2017203258B2 (en)	2019-06-20
CN105188757A (zh)	2015-12-23
TN2015000395A1 (en)	2017-01-03
GT201500295A (es)	2017-09-28
AU2014229265A1 (en)	2015-09-03
KR20150129716A (ko)	2015-11-20
MA38397A1 (fr)	2018-01-31
SG11201506397QA (en)	2015-09-29
PH12015501882A1 (en)	2015-12-07
US9452139B2 (en)	2016-09-27
JP2016512494A (ja)	2016-04-28
CN105188757B (zh)	2019-04-30
IL240963A (en)	2017-05-29
PE20151655A1 (es)	2015-11-26
BR112015021814A2 (pt)	2017-07-18
SA515361055B1 (ar)	2016-11-13
US9744178B2 (en)	2017-08-29
CL2015002632A1 (es)	2016-03-28
EA201591729A1 (ru)	2016-05-31
EP2968570A1 (en)	2016-01-20
US20140302147A1 (en)	2014-10-09
JP6374414B2 (ja)	2018-08-15
US20160354388A1 (en)	2016-12-08
WO2014141135A1 (en)	2014-09-18
CA2905615A1 (en)	2014-09-18

Publication	Publication Date	Title
HK1212616A1 (zh)	2016-06-17	多孔載體顆粒和微粒化藥物的可吸入團聚物
HK1222122A1 (zh)	2017-06-23	選擇性藥物遞送組合物及使用方法
HK1210065A1 (zh)	2016-04-15	乾粉末藥物傳遞系統和方法
EP3052551A4 (en)	2017-09-13	Benefit agent containing delivery particle
IL240291A0 (en)	2015-09-24	History of pyridazinone and pharmaceutical preparations containing them
SG10201705895TA (en)	2017-08-30	Microdevices for separation of non-spherical particles and applications thereof
EP2968825A4 (en)	2016-09-07	GAS STABILIZED PARTICLES AND METHODS OF USE
HK1218855A1 (zh)	2017-03-17	干粉製劑及使用方法
HK1215388A1 (zh)	2016-08-26	可吸入藥用組合物和含有該藥用組合物的吸入器裝置
EP2934134A4 (en)	2016-08-17	DRY POWDER INHALER AND METHODS OF USE
EP3006106A4 (en)	2017-04-26	Catalyst particles, loaded catalyst particles, and use of same
HK1218247A1 (zh)	2017-02-10	益生菌和使用方法
IL240505A0 (en)	2015-09-24	Accumulations of lanthanides and methods for their use
IL244496A0 (en)	2016-04-21	Synthesis and particle engineering of co-crystals
IL276838B (en)	2021-05-31	Oral formulation and suspension of an oncology drug
HK1215167A1 (zh)	2016-08-19	可吸入藥用組合物和含有該藥用組合物的吸入器裝置
IL241070A0 (en)	2015-11-30	Powder particles with additional coating
GB201806558D0 (en)	2018-06-06	Superfically porous particles with precisely controlled particle density and methods of preparation and use thereof
EP3010982A4 (en)	2016-12-21	ENCAPSULATION OF SOLID PARTICLES
GB201307082D0 (en)	2013-05-29	Pharmaceutical composition comprising 15-HETrE and methods of using the same
EP2982465A4 (en)	2016-09-07	METHOD FOR CONTROLLING PARTICLE SIZE OF SILVER PARTICLES, SILVER PARTICLES, ANTIMICROBIOTIC WITH SILVER PARTICLES AND USE THEREOF
AU2013205497B2 (en)	2016-05-12	Dry powder inhaler and methods of use
GB201307659D0 (en)	2013-06-12	Preparation of drug particles by micronisation
GB201312813D0 (en)	2013-08-28	Devices and method for stabilising particle structures for drug delivery